Articles

Safety and efficacy of BNT162b mRNA Covid19 Vaccine in patients with chronic lymphocytic leukemia

Hematology Division, Chaim Sheba Medical Center, Tel-Hashomer; Sackler Faculty of Medicine, Tel-Aviv University, Israel
Department of Software and Information Systems Engineering, Ben-Gurion University of the Negev, Beer-Sheva, Israel
Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center, Petah Tikva, Israel
Department of Hematology Galilee Medical Center, Nahariya, Israel
Hematology Institute, Kaplan Medical Center, Rehovot, Israel
Hematology, Hadassah Medical Center, Jerusalem, Israel
Health Division, Maccabi Healthcare Services, Aviv
Division of Hematology, Ziv Medical Center, Safed, Israel
Hematology Division, Chaim Sheba Medical Center, Tel-Hashomer; Sackler Faculty of Medicine, Tel-Aviv University, Israel
The Infectious Disease Unit, Sheba Medical Center, Tel-Hashomer, Israel; Sackler Faculty of Medicine, Tel-Aviv University, Israel
Central Virology Laboratory, Ministry of Health and Sheba Medical Center, Tel-Hashomer, Israel
Health Division, Maccabi Healthcare Services, Aviv
Department of Hematology and BMT, Rambam Health Care Campus, Haifa, Israel
Infectious Disease Unit, Bnai Zion Medical Center, Haifa, Israel; The Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel
Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center, Petah Tikva, Israel
Hematology, Hadassah Medical Center, Jerusalem, Israel
Hematology Unit, Bnai Zion Medical Center, Haifa, Israel
The Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel; Hematology Unit, Bnai Zion Medical Center, Haifa, Israel
Haematologica Early view Jul 29, 2021 https://doi.org/10.3324/haematol.2021.279196